Sage Journals: Discover world-class research

Abstract

Background:

To evaluate the effects of continuous glucose monitoring (CGM) on nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with multiple daily insulin injections (MDI); we also evaluated factors related to differences in hypoglycemia confidence in this population.

Methods:

Evaluations were performed from the GOLD randomized trial, an open-label multicenter crossover randomized clinical trial (n = 161) over 69 weeks comparing CGM to self-measurement of blood glucose (SMBG) in persons with type 1 diabetes treated with MDI. Masked CGM and the hypoglycemia confidence questionnaire were used for evaluations.

Results:

Time with nocturnal hypoglycemia, glucose levels <70 mg/dL was reduced by 48% (10.2 vs. 19.6 min each night, P < 0.001) and glucose levels <54 mg/dL by 65%. (3.1 vs. 8.9 min, P < 0.001). For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49 min, P < 0.001) and 54% (8 vs. 18 min., P < 0.001), respectively. Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P = 0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P = 0.0020). Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P = 0.0033) and indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P = 0.022).

Conclusion:

CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life. Trial registration: ClinicalTrials.gov, number NCT02092051.

Get full access to this article

View all access options for this article.

References

DCCT Study Group: The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.

Nathan

, Cleary

, Backlund

, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353:2643–2653.

Misso

, Egberts

, Page

, et al.: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev, 2010; 1:CD005103.

Hansen

, Pedersen-Bjergaard

, Heller

, et al.: Frequency and motives of blood glucose self-monitoring in type 1 diabetes. Diabetes Res Clin Pract, 2009; 85:183–188.

Miller

, Beck

, Bergenstal

, et al.: Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care, 2013; 36:2009–2014.

Evans

, Newton

, Ruta

, et al.: Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ, 1999; 319:83–86.

Lind

, Polonsky

, Hirsch

, et al.: Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA, 2017; 317:379–387.

Lind

, Polonsky

, Hirsch

, et al.: Design and methods of a randomized trial of continuous glucose monitoring in persons with type 1 diabetes with impaired glycemic control treated with multiple daily insulin injections (GOLD Study). J Diabetes Sci Technol, 2016; 10:754–761.

Polonsky

, Fisher

, Hessler

, Edelman

: Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol Ther, 2017; 19:131–136.

10.

Hirsch

: Insulin analogues. N Engl J Med, 2005; 352:174–183.

11.

Beck

, Riddlesworth

, Ruedy

, et al.: Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA, 2017; 317:371–378.

12.

Van Beers

, DeVries

, Kleijer

, et al.: Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol, 2016; 4:893–902.

13.

Baghurst

: Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data. Diabetes Tchnol Ther, 2011; 13:296–302.

14.

Bergenstal

, Tamborlane

, Ahmann

, et al.: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med, 2010; 363:311–320.

15.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med, 2008; 359:1464–1476.

16.

JDRF–Study Group: Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. Diabetes Care, 2010; 33:17–22.

17.

Battelino

, Conget

, Olsen

, et al.; SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia, 2012; 55:3155–3162.

18.

Battelino

, Phillip

, Bratina

, et al.: Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care, 2011; 34:795–800.

19.

Pickup

, Freeman

, Sutton

: Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ, 2011; 343:d3805.

20.

Hirsch

: Clinical review: realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab, 2009; 94:2232–2238.

21.

Matuleviciene

, Joseph

, Andelin

, et al.: A clinical trial of the accuracy and treatment experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technol Ther, 2014; 16:759–767.

22.

Kropff

, Bruttomesso

, Doll

, et al.: Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research center and daily life conditions. Diabetes Obes Metab, 2015; 17:343–349.

23.

Damiano

, McKeon

, El-Khatib

, et al.: A comparative effectiveness analysis of three continuous glucose monitors: the navigator, G4 Platinum and Enlite. J Diabetes Sci Technol, 2014; 8:699–708.

24.

Little

, Leelarathna

, Walkinshaw

, et al.: Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injection and continuous with conventional glucose self–monitoring (HypoCOMPaSS). Diabetes Care, 2014:37:2114–2122.

25.

Tan

, Little

, Leelarathna

, et al.: Low-blood glucose avoidance training improves glycemic variability in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: HypoCOMPaSS trial. Diabetes Care, 2016; 39:e56–e58.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB

0.17 MB

0.02 MB

A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia,Daytime Hypoglycemia,Glycemic Variability,and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3)